VACCINE AGAINST COVID-19
History of SARS
Severe Acute Respiratory Syndrome (SARS) is a severe pneumonia caused by a branch of viruses from the coronaviridae family, which were first identified in 2003, when one of these made its appearance in world.
Different Types
of SARS
- SARS-CoV
It could be said that it is the genesis of the cases reported from the coronavirus family. It was first identified in late February 2003 during an outbreak that emerged and spread to other countries, with the first recorded fatal case in Vietnam. Most of the identified SARS patients were previously healthy adults aged 25 to 70 years. A few suspected cases of SARS have been reported among children under 15 years of age. Even today, mortality among people with illnesses that meet the WHO definition for probable and suspected cases of SARS is around 3%.
- SARS-CoV2
Covid-19 and SARS-CoV-2 are closely related (with an identity of 88%) to four endemic coronaviruses and two epidemic coronaviruses that have appeared this century, MERS-CoV and SARS-Cov, that variety of the coronavirus family that first appeared in December 2019. This variant develops severe respiratory complications in the upper thoracic tract, largely affecting the respiratory system. According to WHO studies there were different findings, highlighting possible origins of the virus such as, through an intermediate animal host, followed by a “spillover” through the consumption of refrigerated or frozen foods and direct transmission from an animal source. The term “spillover”in these cases represents possible to probable.
Zifivax™ has been developed by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd. in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences.
Zifivax™ targets the receptor-binding domain (RBD) of SARS-CoV-2 protein S, inducing the production of neutralizing antibodies in humans through recombinant expression of the RBD protein, thus blocking the binding of the SARS-CoV-2 to the host cell surface ACE2 receptor, achieving the purpose of preventing infection.
Zifivax™ recombinant protein subunit vaccine of patented technology is free of nucleic acid components of the virus, with a greater guarantee of biosafety.
Zifivax™ vs. Variants
Alfa
It was shown to be at least 50% more transmissible than older lineages. Alpha’s runaway success has scientists wondering how this variant took the world by storm. A recent study mentions one of the secrets of its success, Alpha disables the first line of immune defense in our body, so the virus has more time to multiply.
Zifivax™ vs. Alpha = 92.93% effectiveness.
Delta
As highlighted in international reports, Delta is the predominant variant globally. The greatest risk of transmission is among unvaccinated people. People who get the virus after vaccination can also spread COVID-19 to other people. However, it appears that vaccinated people transmit it for a shorter period of time than unvaccinated people.
Zifivax™ vs. Delta = 77.54% effectiveness.
Omicron
This new iteration of the coronavirus, first identified in Botswana and South Africa, has now spread across the world. Scientists first recognized the omicron variant thanks to its distinctive combination of more than 50 mutations. Some of them were carried by earlier variants, such as alpha and beta, and previous experiments had shown that such mutations could allow a coronavirus to spread rapidly.
Zifivax ™ vs. Omicron = High effectiveness. (According to Current Studies)
Applied doses
Zifivax™ is free of any component of the viral nucleic acid and therefore does not present a risk of reversal of virulence, with a much higher biosafety than traditional vaccines.
Unique patented technology to significantly improve immunogenicity.
Zifivax™ applies its unique patented dimeric RBD technology, significantly improving immunogenicity compared to conventional monomeric RBD.
Advanced and complete production process
The vaccine uses recombinant gene technology to express a specific antigen that is both advanced and mature, in a process similar to the one used to produce the known hepatitis B, HPV, Hepatitis E, HPV and Herpes Zoster vaccines.
Storage and transport between 2 and 8°C
Zifivax™ can be stored at temperatures between 2 and 8°C. Avoiding exposure to light, the shelf life of the vaccine is 2 years, which is convenient for storage, transportation and use.
Zifivax™ has been under observation at 37°C土2°C for 28 days and all indicators met regulatory requirements.
Study and Research
Effects of booster doses of ZIFIVAX™ in the neutralization of the Omicron Variant over a prolonged interval.*
*Studies published in The New England Journal of Medicine. Copyright © 2022 Massachusetts Medical Society
Figure 1. Serum IgG Titers and Pseudovirus Neutralization against the Omicron Variant. Serum samples were obtained from persons who had recovered from coronavirus disease 2019 (the convalescent group) or persons who had received three doses of an inactivated vaccine or the ZF2001 protein
subunit vaccine. These samples were tested for binding and neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prototype and variants of concern (B.1.1.7 [or alpha], B.1.351 [or beta], B.1.617.2 [or delta], and B.1.1.529 [or omicron]).
Panels A through D show the titers of serum IgG antibodies against the SARS-CoV-2 prototype strain or the omicron trimeric spike protein. The persons in the inactivated-vaccine group received the second priming dose 1 month after the first dose and then the third dose more than 6 months after the second dose. The persons in the short-interval ZF2001 group received the second priming dose 1 month after the first dose and then the third dose 1 month after the second dose. The persons in the prolonged-interval ZF2001 group received the second priming dose 1 month after the first dose and then the third dose 4 months after the second dose. A total of 8 samples from 8 persons were tested in each group.
Figure 2
Neutralizing Antibodies against Omicron Variant.
Panel E shows the percentage of samples that tested positive (as indicated by a titer of >1:20) for neutralizing antibodies against the omicron variant. “Prolonged-interval ZF2001 4–6 Mo” refers to the 13 serum samples from vaccinees who also had a prolonged interval between the second and third dose but were collected 4 to 6 months after the third dose.
Contact us
ProEnterprises Colombia S.A.S
Calle 100 # 19A-50
Edf. International Tower Ofc. 704
Bogota, Colombia
LatAm Affiliates:
• Ecuador
• Peru